Overview Dividends

(ARCT) Arcturus Therapeutics - Ratings and Ratios

Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US03969T1097

Vaccine, mRNA, Liver, Respiratory

ARCT EPS (Earnings per Share)

EPS Growth (3Y CAGR): -34.26%
EPS Trend (3Y Correlation): -43.0%

ARCT Revenue

Revenue Growth (3Y CAGR): 31.35%
Revenue Trend (3Y Correlation): -15.0%

Description: ARCT Arcturus Therapeutics October 25, 2025

Arcturus Therapeutics Holdings (NASDAQ: ARCT) is a San Diego-based biotech that leverages its LUNAR lipid-nanoparticle delivery system and STARR mRNA platform to develop both infectious-disease vaccines and therapeutics for rare liver and respiratory disorders.

The pipeline centers on mRNA-based candidates: ARCT-810 (LUNAR-OTC) for ornithine transcarbamylase deficiency and ARCT-032 (LUNAR-CF) for cystic fibrosis, both in Phase 2; a COVID-19 vaccine (KOSTAIVE) in late-stage trials; and a suite of influenza programs (LUNAR-FLU, LUNAR-H5N1, and bivalent/monovalent candidates) ranging from Phase 1 to Phase 3.

As of the most recent 10-Q (Q2 2024), Arcturus reported $210 million in cash and equivalents, giving it roughly 18 months of runway at its current burn rate of $12 million per quarter. The mRNA therapeutics market is projected to grow at a CAGR of ~30 % through 2030, while rare-disease gene-therapy spend in the U.S. exceeds $10 billion annually-both macro trends that could expand the addressable market for ARCT’s candidates. However, the company’s valuation remains highly sensitive to clinical readouts, and its current market cap (~$1.1 billion) implies a price-to-sales multiple of ~15× on projected 2025 revenues, which is above the sector median.

For a data-driven, independent view of ARCT’s upside and downside risks, you may find ValueRay’s analyst framework a useful next step.

ARCT Stock Overview

Market Cap in USD	253m
Sub-Industry	Biotechnology
IPO / Inception	2020-04-16

ARCT Stock Ratings

Growth Rating	-52.7%
Fundamental	15.8%
Dividend Rating	-
Return 12m vs S&P 500	-59.2%
Analyst Rating	4.73 of 5

ARCT Dividends

Currently no dividends paid

ARCT Growth Ratios

Growth Correlation 3m	-11.7%
Growth Correlation 12m	-10.6%
Growth Correlation 5y	-62%
CAGR 5y	-22.43%
CAGR/Max DD 3y (Calmar Ratio)	-0.28
CAGR/Mean DD 3y (Pain Ratio)	-0.58
Sharpe Ratio 12m	-0.67
Alpha	-84.81
Beta	2.074
Volatility	73.12%
Current Volume	1177.1k
Average Volume 20d	1153k
Stop Loss	8.1 (-7.1%)
Signal	-1.03

Piotroski VR‑10 (Strict, 0-10) 1.0

Net Income (-60.2m TTM) > 0 and > 6% of Revenue (6% = 7.05m TTM)

FCFTA -0.21 (>2.0%) and ΔFCFTA -2.71pp (YES ≥ +1.0pp, WARN ≥ +0.5pp)

NWC/Revenue 194.0% (prev 173.6%; Δ 20.40pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp)

CFO/TA -0.21 (>3.0%) and CFO -64.9m <= Net Income -60.2m (YES >=105%, WARN >=100%)

NO Net Debt/EBITDA fails (EBITDA <= 0)

Current Ratio 5.90 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active)

Outstanding Shares last Quarter (27.1m) change vs 12m ago 0.60% (target <= -2.0% for YES)

Gross Margin 98.54% (prev 97.67%; Δ 0.86pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0)

Asset Turnover 33.67% (prev 37.83%; Δ -4.16pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0)

Interest Coverage Ratio -3.27 (EBITDA TTM -55.3m / Interest Expense TTM 14.1m) >= 6 (WARN >= 3)

Altman Z'' -7.37

(A) 0.74 = (Total Current Assets 274.5m - Total Current Liabilities 46.5m) / Total Assets 309.3m

(B) -1.53 = Retained Earnings (Balance) -472.1m / Total Assets 309.3m

warn (B) unusual magnitude: -1.53 — check mapping/units

(D) -6.03 = Book Value of Equity -472.0m / Total Liabilities 78.2m

Total Rating: -7.37 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D)

ValueRay F-Score (Strict, 0-100) 15.77

1. Piotroski 1.0pt = -4.0

2. FCF Yield -81.58% = -5.0

3. FCF Margin -55.04% = -7.50

4. Debt/Equity 0.10 = 2.50

5. Debt/Ebitda 3.14 = -1.95

6. ROIC - WACC (= -31.35)% = -12.50

7. RoE -24.87% = -2.50

8. Rev. Trend -15.02% = -1.13

9. EPS Trend -42.96% = -2.15

What is the price of ARCT shares?

As of November 09, 2025, the stock is trading at USD 8.72 with a total of 1,177,085 shares traded.
Over the past week, the price has changed by -12.54%, over one month by -57.40%, over three months by -27.21% and over the past year by -53.47%.

Is Arcturus Therapeutics a good stock to buy?

No, based on ValueRay´s Fundamental Analyses, Arcturus Therapeutics (NASDAQ:ARCT) is currently (November 2025) a stock to sell. It has a ValueRay Fundamental Rating of 15.77 and therefor a negative outlook according to the companies health.
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of ARCT is around 6.63 USD . This means that ARCT is currently overvalued and has a potential downside of -23.97%.

Is ARCT a buy, sell or hold?

Arcturus Therapeutics has received a consensus analysts rating of 4.73. Therefore, it is recommended to buy ARCT.

Strong Buy: 8
Buy: 3
Hold: 0
Sell: 0
Strong Sell: 0

What are the forecasts/targets for the ARCT price?

Issuer	Target	Up/Down from current
Wallstreet Target Price	44.8	413.2%
Analysts Target Price	44.8	413.2%
ValueRay Target Price	7.7	-12.3%

ARCT Fundamental Data Overview November 06, 2025

Market Cap USD = 252.8m (252.8m USD * 1.0 USD.USD)
P/E Forward = 2.4777
P/S = 2.0701
P/B = 2.5714
Beta = 2.074
Revenue TTM = 117.5m USD
EBIT TTM = -46.2m USD
EBITDA TTM = -55.3m USD
Long Term Debt = 15.0m USD (from longTermDebt, two quarters ago)
Short Term Debt = 7.10m USD (from shortTermDebt, last fiscal year)
Debt = 22.9m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -173.5m USD (from netDebt column, last quarter)
Enterprise Value = 79.3m USD (252.8m + Debt 22.9m - CCE 196.5m)
Interest Coverage Ratio = -3.27 (Ebit TTM -46.2m / Interest Expense TTM 14.1m)
FCF Yield = -81.58% (FCF TTM -64.7m / Enterprise Value 79.3m)
FCF Margin = -55.04% (FCF TTM -64.7m / Revenue TTM 117.5m)
Net Margin = -51.20% (Net Income TTM -60.2m / Revenue TTM 117.5m)
Gross Margin = 98.54% ((Revenue TTM 117.5m - Cost of Revenue TTM 1.72m) / Revenue TTM)
Gross Margin QoQ = 100.0% (prev 100.0%)
Tobins Q-Ratio = 0.26 (Enterprise Value 79.3m / Total Assets 309.3m)
Interest Expense / Debt = 61.69% (Interest Expense 14.1m / Debt 22.9m)
Taxrate = -0.04% (negative due to tax credits) (4000 / -9.18m)
NOPAT = -46.3m (EBIT -46.2m * (1 - -0.04%)) [loss with tax shield] [negative tax rate / tax credits]
Current Ratio = 5.90 (Total Current Assets 274.5m / Total Current Liabilities 46.5m)
Debt / Equity = 0.10 (Debt 22.9m / totalStockholderEquity, last quarter 231.1m)
Debt / EBITDA = 3.14 (negative EBITDA) (Net Debt -173.5m / EBITDA -55.3m)
Debt / FCF = 2.68 (negative FCF - burning cash) (Net Debt -173.5m / FCF TTM -64.7m)
Total Stockholder Equity = 241.9m (last 4 quarters mean from totalStockholderEquity)
RoA = -19.45% (Net Income -60.2m / Total Assets 309.3m)
RoE = -24.87% (Net Income TTM -60.2m / Total Stockholder Equity 241.9m)
RoCE = -18.00% (EBIT -46.2m / Capital Employed (Equity 241.9m + L.T.Debt 15.0m))
RoIC = -18.83% (negative operating profit) (NOPAT -46.3m / Invested Capital 245.7m)
WACC = 12.52% (E(252.8m)/V(275.7m) * Re(13.66%) + (debt cost/tax rate unavailable))
Discount Rate = 13.66% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 0.94%
Fair Price DCF = unknown (Cash Flow -64.7m)
EPS Correlation: -42.96 | EPS CAGR: -34.26% | SUE: -3.56 | # QB: 0
Revenue Correlation: -15.02 | Revenue CAGR: 31.35% | SUE: 0.33 | # QB: 0

Additional Sources for ARCT Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle